RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Jazz Pharmaceuticals Stock

Jazz Pharmaceuticals P/S 2025

Jazz Pharmaceuticals P/S

1.96

Ticker

JAZZ

ISIN

IE00B4Q5ZN47

WKN

A1JS1K

As of Feb 7, 2025, Jazz Pharmaceuticals's P/S ratio stood at 1.96, a 5.95% change from the 1.85 P/S ratio recorded in the previous year.

The Jazz Pharmaceuticals P/S history

Jazz Pharmaceuticals Aktienanalyse

What does Jazz Pharmaceuticals do?

Jazz Pharmaceuticals PLC is a global biopharmaceutical company specializing in treating life-threatening diseases. The company was founded in 2003 in Ireland and now operates in Europe, North America, and other parts of the world. Jazz's business model focuses on offering innovative therapies for diseases that have no cure or unsatisfactory existing treatments. The company has a well-planned pipeline of high-quality products, supported by excellent customer service and innovative marketing strategies. Jazz holds numerous patents for various medications that can be used for different medical purposes. The company offers four different medical specialties: hematology-oncology, narcolepsy, pain medicine, and psychiatric disorders. Its most well-known specialty is hematology-oncology, where Jazz concentrates on developing therapies for hematological cancers such as leukemia, lymphomas, and myeloma. Furthermore, Jazz provides medications for rare diseases such as Gaucher's disease and Fabry disease. In the field of pain medicine, Jazz Pharmaceuticals has developed specific therapies for patients with sleep disorders and pain. The company also offers treatments for depressive disorders and obsessive-compulsive disorders. Another important area for Jazz is the development of medications for patients suffering from narcolepsy, a condition that causes constant fatigue and sudden sleep attacks, significantly impacting daily life for many patients. One of Jazz Pharmaceuticals' most well-known products is Xyrem, which is used to treat narcolepsy. Xyrem is a potent sedative with a high potential for addiction and can only be prescribed by qualified doctors. Another key product from Jazz is Vyxeos, a medication for the treatment of acute myeloid leukemia, an aggressive form of blood cancer typically difficult to treat. Vyxeos is a dual-action medication that can significantly improve the survival chances of leukemia patients. Jazz Pharmaceuticals is a global leader in hematology-oncology and has become a significant player in the market for medical therapies in recent years. The company currently employs over 1,500 employees and is listed on the NASDAQ. Its headquarters are located in Dublin, Ireland. Jazz Pharmaceuticals is dedicated to supporting patients worldwide with high-quality medical products and services. Jazz Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Jazz Pharmaceuticals's P/S Ratio

Jazz Pharmaceuticals's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Jazz Pharmaceuticals's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Jazz Pharmaceuticals's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Jazz Pharmaceuticals’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Jazz Pharmaceuticals stock

What is the price-to-earnings ratio of Jazz Pharmaceuticals?

The price-earnings ratio of Jazz Pharmaceuticals is currently 1.96.

How has the price-earnings ratio of Jazz Pharmaceuticals changed compared to last year?

The price-to-earnings ratio of Jazz Pharmaceuticals has increased by 5.95% increased compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Jazz Pharmaceuticals high compared to other companies?

Yes, the price-to-earnings ratio of Jazz Pharmaceuticals is high compared to other companies.

How does an increase in the price-earnings ratio of Jazz Pharmaceuticals affect the company?

An increase in the price-earnings ratio of Jazz Pharmaceuticals would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Jazz Pharmaceuticals affect the company?

A decrease in the price-earnings ratio of Jazz Pharmaceuticals would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Jazz Pharmaceuticals?

Some factors that influence the price-earnings ratio of Jazz Pharmaceuticals are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Jazz Pharmaceuticals pay?

Over the past 12 months, Jazz Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Jazz Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Jazz Pharmaceuticals?

The current dividend yield of Jazz Pharmaceuticals is .

When does Jazz Pharmaceuticals pay dividends?

Jazz Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Jazz Pharmaceuticals?

Jazz Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Jazz Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Jazz Pharmaceuticals located?

Jazz Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Jazz Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Jazz Pharmaceuticals from 2/7/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/7/2025.

When did Jazz Pharmaceuticals pay the last dividend?

The last dividend was paid out on 2/7/2025.

What was the dividend of Jazz Pharmaceuticals in the year 2024?

In the year 2024, Jazz Pharmaceuticals distributed 0 USD as dividends.

In which currency does Jazz Pharmaceuticals pay out the dividend?

The dividends of Jazz Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Jazz Pharmaceuticals

Our stock analysis for Jazz Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Jazz Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.